OSCIENT PHARMACEUTICALS CORPORATION COMPLETES ACQUISITION OF CARDIOVASCULAR THERAPY ANTARA 130MG (FENOFIBRATE) CAPSULES

Oscient Pharmaceuticals has completed its acquisition of the U.S. rights to the cardiovascular product ANTARA 130 mg (fenofibrate) capsules from Reliant Pharmaceuticals. ANTARA is part of the $22 billion U.S. market for treating dyslipidemias, which includes the $1 billion fenofibrate market. ANTARA will be commercialized by Oscient's national sales force beginning later this week.
BioSpace